Greetings to Benzinga’s weekly roundup of psychedelic pharmaceutical headlines. Here, we gather the most captivating news from the second week of January 2024.
Lykos Therapeutics, previously known as MAPS PBC, unveiled a groundbreaking study on the effects of MDMA-assisted therapy on emotional coping skills and self-experience in PTSD (read.)
An Australian study explored the potential therapeutic effects of an ayahuasca-inspired N, N-DMT and harmine formulation in a controlled trial involving healthy subjects (read.)
A preliminary report investigated the antidepressant effects of vaporized DMT in treatment-resistant depression (read.)
Chinese government-backed research delved into psilocybin’s cell-type-specific changes in the orbitofrontal cortex (read.)
Exploration of the perceived risk of trying LSD in the U.S. from 2015 to 2019 raised questions on the changing risk perception of LSD among Americans (read.)
A new review shed light on the potential of psychedelics for acquired brain injury treatment (read.)
The existence of knowledge gaps in psychedelic medicalization was observed, focusing on clinical studies and regulatory aspects (read.)
Imperial College London’s exploration of psilocybin’s effects on gamblers’ brain dysfunction piqued interest (read.)
A qualitative survey study delved into coping and support strategies used by individuals dealing with extended difficulties after the use of psychedelic drugs, led by researcher Jules Evans (preprint.)
UC Berkeley’s Center for the Science of Psychedelics announced the opening of applications for research proposals on “Psychedelics in Society and Culture” (participate.)
Imperial College London initiated a psychedelic survey titled “The Breathwork Study 2024” (participate.)
Johns Hopkins University launched new psilocybin research seeking participants in Baltimore with opioid use disorder (apply.)
The University of Texas embarked on new psychedelic retreat research focused on women currently grieving the loss of a loved one (participate.)
The FDA’s Reagan-Udall Foundation is gearing up to hold a virtual public workshop titled “Advancing Psychedelic Clinical Study Design” on Jan. 31 and Feb. 1 (participate.)
DoubleBlind is hosting a free workshop on Tripping for Partners with Dr. Ido Cohen on Jan. 21 (participate.)
Celebstoner’s Steve Bloom listed “The 12 Best Cannabis/Drug Books of 2023” in a thought-provoking year in review article (read.)
The Wall Street Journal’s David Wainer provided insights into the landscape of psychedelics investments (read.)
Carolyn Beans explored the healing potential of psychedelics and featured interviews with Dr. Ceyda Sayali and Dr. Albert Garcia-Romeu in her review “If psychedelics heal, how do they do it?” (read.)
Dr. Peter Grinspoon analyzed ketamine, presenting a comprehensive review on its uses, benefits, and risks (read.)
Jules Evans provided insights into communicating the risks of psychedelics (read.)
A captivating discussion on “Psychedelics and Philosophy: Metaphysics and Meaning-Making in Psychedelia” was held at Harvard Divinity School, featuring Dr. Peter Sjöstedt-Hughes and Prof. Christine Hauskeller (listen.)
David B. Yaden and Katherine Cheung articulated the need for metaphysics in psychedelic therapy and research in their commentary (read.)
HealingMaps’ Cory Jones shed light on 15 surprising statistics about psychedelic therapy’s mental health impact (read.)
Insights into the psychedelic legalization debate in the UK were shared in an article titled “Psychedelic Law: As the Psychedelic Legalization Debate Rages in the UK, People Suffer” (read.)
An analysis revealed strong bipartisan support for controlled Psilocybin use as treatment or enhancement in a representative sample of US Americans, urging caution in public policy (read.)
Former KYOAAC leader Bryan Hubbard discussed Kentucky’s potential for opioid addiction treatment development (read.)
The Wall Street Journal reviewed Elon Musk’s use of drugs, drawing concerns from leaders at Tesla and SpaceX (read.)
Sam Woolfe delved into “Seeing the World Anew: Psychedelics, Child-Like Wonder, and the Will to Novelty” in his compelling article (read.)
Psychedelic Spotlight explored the causes, symptoms, and treatment of tetany, aka hand cramps during a psychedelic experience in their feature article (read.)
Josh Hardman unraveled the mysterious advisory panel blocking dozens of psychedelic studies in California (read.)
DoubleBlind chronicled the journey of “Moxy: The Novel Psychedelic” and its battle against a DEA ban (read.)
Big Think shared insights into the potential effects of DMT on cardiac activity in their article “The psychedelic heart” (read.)
Vox’s Sean Illing interviewed neuroscientist Gul Dolen, unraveling how psychedelics can reinvent the brain (listen.)
The Dennis McKenna Academy hosted a thought-provoking podcast episode featuring author Chris Ryan’s take on civilization (listen.)
The Psychedelics Today podcast engaged in a captivating discussion on reinventing organizations, lessons from Burning Man, and Batman & The Joker (listen.)
A significant ruling saw a California judge going against the feds in a psychedelic tea case (read.)
DoubleBlind shared the Navajo Nation’s perspective on funerals on the moon (read.)
Jules Evans penned an intriguing article on the theology of ‘meh’ experiences (read.)
PharmAla Biotech’s MDMA molecule PharmAla-1 received the U.S. patent office’s green light for fast-track IP application review (PMBHF, OTC)
Lobe Sciences made strides, impressively featuring as an intriguing company in the psychedelic space (LOBEF, OTC)
Psychedelic Medicine Companies Shake Up Market
Psychedelic Medical Research Company (PMRC) released its 2023 review, unveiling 12-month data confirming that L-130 is the first stable oral psilocin derivative developed for therapeutic use.
Usona Institute’s recent research has revealed novel compounds sourced from mushrooms with observed psychedelic-like activity.
Clearmind Medicine CMND successfully completed a Type A meeting with the FDA, advancing its proprietary MEAI-based molecule for alcohol use disorder treatment.
PharmaTher Holdings PHRRF anticipates FDA approval of ketamine by April 29, 2024.
Compass Pathways CMPS and TMS and Spravato provider Greenbrook TMS have entered a three-year research collaboration to develop scalable, commercial delivery models for psilocybin treatment.
The DEA recently closed the public comment period on its proposal to classify psychedelic compounds DOI and DOC, widely used in scientific research, as Schedule I substances.
Cybin CYBN CEO, Doug Drysdale, has joined the Deepak Chopra Foundation to discuss how media shapes public awareness of psychedelics.
Atai Life Sciences ATAI CEO, Christian Angermayer, expressed confidence in consolidating various major psychedelics under one company.
Atai’s “best-kept secret”: IntelGenX IGXT has been featured by Psychedelic Insights in a recent article.
Alex Carchidi’s analysis of key sector catalysts indicates that companies such as Compass Pathways, Cybin, and Atai are the most sensible choices for investors at this point.
The McKenna Academy’s documentary “Biognosis” has been nominated for the British Columbia Environmental Film Festival.
Research and education nonprofits Realm of Caring and Unlimited Sciences have collaborated with Lily’s Lighthouse to explore the efficacy of functional mushrooms in treating epilepsy in children.
Author Brandi Sellerz-Jackson shared her ketamine therapy experience in an article published in Oprah Daily.